Author: Ravi Shankar

New operation expands TTEC’s automotive CX capabilities in Egypt as part of a seven-year strategic collaboration with Volkswagen Group UK Ltd.

AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) — TTEC, a leading global consulting, technology, and managed services company delivering solutions at the intersection of data, AI, and customer experience (CX), today announced the launch of a new customer experience operation in Cairo supporting Volkswagen Group UK Ltd. (VWG).

The new operation expands TTEC’s automotive CX capabilities in Egypt and supports VWG’s customer care operations across digital and voice channels. The program will leverage TTEC’s multilingual workforce, automotive expertise, and AI-enabled CX capabilities to help deliver connected and consistent experiences for VWG customers.

“Providing a seamless customer experience is integral to how we support our customers and our brands,” said Chris Stevens, Volkswagen Group UK Head of Customer Management. “The launch of this operation in Cairo with TTEC gives us access to skilled talent and capabilities that will help us deliver consistent, high-quality support as our customer needs continue to evolve.”

The Cairo launch is part of a new seven-year strategic collaboration between TTEC and VWG, announced earlier this year. The agreement expands TTEC’s role in supporting VWG’s customer experience operations and includes customer care, case management, connected vehicle support, and digital engagement.

The development complements Volkswagen Group UK’s broader CX strategy, with teams positioned across multiple locations to best support the Group’s customers. The Cairo operation adds to that network while bringing TTEC’s multilingual CX expertise and automotive experience to the Group’s customer operations.

TTEC entered Egypt in 2023 and has continued to expand its presence, including the opening of a state-of-the-art facility in Maadi Technology Park. TTEC Egypt supports multilingual customer experience, technical support, AI-enabled services and back-office operations for global clients. TTEC currently supports 11 languages in Egypt, including Arabic, English, French, German, Italian and Spanish.

“Cairo has quickly become a key hub for multilingual global CX, and we’re excited to continue our longstanding relationship with Volkswagen Group UK in Egypt,” said John Abou, CEO, TTEC Engage. “TTEC brings together a highly skilled workforce, AI-enabled technology and decades of automotive expertise to create a customer experience that differentiates the ownership experience across Volkswagen brands.”

The launch further strengthens TTEC’s position as a CX partner for the automotive industry and expands its ability to support automotive customers across the customer lifecycle. It also reflects TTEC’s continued investment in Egypt as a strategic delivery hub connecting Europe, the Middle East, and Africa. In 2025, TTEC announced plans to expand its Egyptian workforce by an additional 3,500 employees by 2029 to meet growing global demand for multilingual CX and digital services.

About TTEC

TTEC Holdings, Inc. (NASDAQ: TTEC) is a leading global consulting, technology, and managed services company delivering solutions at the intersection of data, AI, and customer experience. Serving iconic and disruptive brands, TTEC’s outcome-based solutions span the entire enterprise, touch every virtual interaction channel, and improve each step of the customer journey. Leveraging next-generation digital technology, the Company’s TTEC Digital business designs, builds, and operates omnichannel contact center technology, CRM, AI, and analytics solutions. The Company also delivers AI-enhanced customer engagement, customer acquisition and growth, tech support, back-office, and fraud prevention services. Founded in 1982, TTEC’s singular obsession with CX excellence has earned it leading client, customer, and employee satisfaction scores across the globe. The Company’s employees operate on six continents and bring technology and humanity together to deliver happy customers and differentiated business results. To learn more, visit ttec.com.

Media Contact
Meredith Matthews
meredith.matthews@ttec.com 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dbd050a7-e7e3-4d50-8ce7-b84a63938298

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — newcleo plc (“newcleo” or the “Company”), a pioneer in advanced modular reactor (“AMR”) technology and nuclear fuel manufacturing, announced that its ordinary shares and warrants will begin trading on the Nasdaq Global Select Market today, September 22, 2026, under the ticker symbols “NWCL” and “NWCLW”, respectively.

“Today marks a pivotal milestone for newcleo as we bring our technology to the public markets,” said Stefano Buono, CEO and co-founder of newcleo. “As a Nasdaq-listed company, we have the capital and the platform to accelerate deployment of our reactor and fuel manufacturing technology across Europe and the United States, and to advance our mission of closing the nuclear fuel cycle. We could not be more excited to kick off this next chapter of our company’s history.”

newcleo’s Nasdaq listing will support its global growth, completing and operating its 10MWth non-nuclear demonstrator in Italy, advancing regulatory and licensing interactions with U.S. and French nuclear safety regulators, and to continue pursuing commercial opportunities to deploy its reactors and fuel manufacturing facilities in the U.S. and Europe.

About newcleo

newcleo is an innovative nuclear technology company developing advanced modular reactors and nuclear fuel designed to deliver clean, safe and sustainable energy at competitive costs. newcleo’s technology combines lead-cooled fast reactors with fuel manufactured from recycled nuclear materials, with the aim of providing abundant and reliable electricity and heat to industrial users while enabling the closure of the nuclear fuel cycle. newcleo brings together more than 900 highly skilled employees across Europe and the United States, spanning reactor and fuel design, engineering, and manufacturing. Through a vertically integrated supply chain and a growing network of strategic partnerships, newcleo is working to turn proven scientific and engineering solutions into deployable nuclear energy assets. For more information visit www.newcleo.com.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the U.S. federal securities laws. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding the completed business combination between NewHold Investment Corp III and newcleo; the anticipated benefits of the transaction; expected trading of the combined company’s securities on Nasdaq; the completion of investments from certain institutional investors; the expected amount of gross proceeds from any investments or other financing arrangements; the anticipated use of proceeds from such investments or financing arrangements; newcleo’s development and commercialization of its lead-cooled fast reactor technology, mixed-oxide fuel capabilities and related products and services; the expected timing, cost, performance and benefits of newcleo’s demonstration projects, fuel facilities, reactor deployments and licensing activities; newcleo’s ability to execute its business strategy, develop its technology, obtain required regulatory approvals, permits and licenses, enter into commercial arrangements, achieve its market opportunity and positioning and support the growth of advanced nuclear energy; newcleo’s expectations regarding strategic partnerships, customer demand, project pipeline, revenue streams, capital expenditures and financing needs; and other statements regarding management’s intentions, beliefs, or expectations with respect to newcleo’s future performance, are forward-looking statements. Forward-looking statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “develop,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on newcleo’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. You should carefully consider the foregoing factors and the other risks and uncertainties described in other documents filed from time to time by newcleo with the U.S. Securities and Exchange Commission. Additional risks and uncertainties not currently known or that are currently deemed immaterial may also cause actual results to differ materially from those expressed or implied by such forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and newcleo does not assume any obligation or intend to update or revise these forward-looking statements, each of which is made only as of the date of this press release.

For enquiries

Investor contact
newcleo@icrinc.com

Media contact
newcleo press office: media@newcleo.com
U.S. media inquiries: newcleo@icrinc.com

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend the corporate presentation at https://lythampartners.com/fall2026/

CUPERTINO, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced today that Laxminarayan Bhat, PhD., Founder, President and CEO, will present will participate in a webcast presentation at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

DATE: September 29^th
TIME: 12:30 PM ET

Company Webcast

The webcast presentation will take place at 12:30 PM ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/vNl8PQxLKqg. The webcast will also be available for replay following the event.

1×1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at rvph@lythampartners.com or register for the event at https://lythampartners.com/fall2026invreg/.

About Reviva

Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company’s plans for its brilaroxazine program including intended steps of advancing clinical development and regulatory strategy towards potential approval, statements about the Company’s planned registrational RECOVER-2 Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia, statements about the Company’s planned use of a new form of brilaroxazine in its RECOVER-2 Phase 3 trial and in its future NDA submission, statements about anticipated FDA feedback, and the projected timing of the foregoing, statements about the Company’s planned bioequivalence study, statements about the expected timing of initiation of patient enrollment in the RECOVER-2 Phase 3 trial, statements about the Company’s strategy to strengthen the long-term value of brilaroxazine and the potential to extend patent protection and commercial exclusivity, including the expected duration thereof, statements about potential future NDA and other future regulatory submissions, statements about the Company’s expectations regarding the anticipated clinical profile of its product candidates, including statements regarding anticipated efficacy or safety profile, and those relating to the Company’s expectations, intentions or beliefs regarding matters including product development and clinical trial plans and the timing thereof, including the anticipated timing of the availability of trial data, clinical and regulatory timelines and expenses, planned or intended additional trials or studies and the timing thereof, planned or intended regulatory submissions and the timing thereof, or trial data or results or the implications thereof generally, statements about the quotation of the Company’s common stock on the OTCQB Venture Market (which is subject to additional risks compared to being listed on a national securities exchange including the Company’s ability to maintain compliance with the standards for continued quotation on the OTC Markets, together with limited liquidity, increased volatility, sporadic trading in the public market for the Company’s common stock, and that the Company’s ability to raise additional capital while trading on the OTC Markets may be adversely impacted), statements about market opportunity, ability to raise sufficient funding, the Company’s cash position and its projected cash runway, statements about competitive position, possible or assumed future results of operations, business strategies, potential opportunities for development including partnerships, growth or expansion opportunities, and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2025, the Company’s Quarterly Reports on Form 10-Q filed since such Annual Report on Form 10-K, and the Company’s other filings from time to time with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com

About Lytham Partners
Lytham designs one of the most effective platforms for public companies to communicate corporate information to the largest and most appropriate cross section of institutional investors. Combining Corporate Positioning, Corporate Access & Consulting Services, our platform offers a level of shareholder value that remains competitive in the industry. 

Lytham Partners
Ben Shamsian CPA

Vice President, Investor Relations
Lytham Partners, LLC
shamsian@lythampartners.com

Expands programmatic access to 800,000 verified prescribers directly in the EHR workflow, making OptimizeRx’s point of care inventory directly available to advertisers using The Trade Desk

WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) — OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced an integration with OpenPath, The Trade Desk’s supply path optimization solution, making OptimizeRx’s authenticated point of care inventory available directly to advertisers using The Trade Desk’s leading, data-driven demand side platform (DSP).

Through OpenPath, advertisers using The Trade Desk will gain direct access to OptimizeRx’s proprietary network of more than 400 electronic health record (EHR) and e-prescribe systems, reaching 800,000 verified HCPs. The integration expands the differentiated healthcare inventory available to life sciences advertisers on The Trade Desk, enabling them to incorporate OptimizeRx’s point of care inventory into their broader programmatic media strategies.

Bringing Point of Care into Mainstream Programmatic Buying Through OpenPath

Historically, EHR advertising inventory has been primarily purchased through direct, managed-service relationships or specialized healthcare platforms, which has made it challenging to incorporate into many brands’ omnichannel marketing strategies. By integrating with OpenPath, OptimizeRx can make its point of care inventory directly available to advertisers using The Trade Desk, providing another way for life sciences marketers to incorporate HCP media into their broader programmatic strategies.

OpenPath provides advertisers with a direct connection to premium publisher inventory, helping improve transparency and efficiency across the advertising supply chain. OptimizeRx’s integration extends that direct access to its EHR point of care network alongside the broader range of digital media advertisers can buy through The Trade Desk. As a result, advertisers can incorporate in-workflow placements into a buying infrastructure already central to their broader media strategy.

“Point of care has matured beyond a specialty media buy, and the next step is integrating it into the way all HCP media is planned and bought,” said Stephen Silvestro, CEO, OptimizeRx. “By integrating with OpenPath, we can make our authenticated clinical inventory directly accessible to a broader base of advertisers using The Trade Desk, without losing what makes that inventory distinct: verified providers, real clinical workflows, and proximity to the treatment decision.”

“Life sciences advertisers increasingly want greater choice and direct access to the differentiated inventory that matters to their campaigns,” said Baron Harper, VP, Business Development, The Trade Desk. “By connecting OptimizeRx’s point of care network to OpenPath, advertisers can access authenticated HCP inventory directly through The Trade Desk and incorporate it alongside their broader media investments. This gives advertisers more flexibility in how they reach healthcare professionals while bringing another differentiated source of supply to the open internet.”

Building a Broader Programmatic Distribution Network for Point of Care

The OpenPath integration is the latest step in OptimizeRx’s broader programmatic distribution strategy for its proprietary EHR network. By creating multiple buyer entry points, OptimizeRx can reach new sources of advertiser demand, give life sciences marketers greater flexibility in how they access the network, and make EHR inventory more broadly available across the programmatic HCP ecosystem.

Availability

OptimizeRx’s EHR point of care inventory is expected to be available to advertisers using The Trade Desk through OpenPath in the fourth quarter of 2026.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood® Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “brings”, “expands”, “will”, “can”, “enabling”, “integrating”, “helping”, “improve” or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the availability of OptimizeRx’s EHR inventory on the Trade Desk through OpenPath, advertisers’ ability to directly connect to premium publisher inventory which will help improve transparency and efficiency across advertising supply chains, marketers’ ability to incorporate in-workflow placements into their current buying infrastructure, the Company’s ability to make its authenticated clinical inventory directly accessible to a broader base of advertisers without losing what makes the inventory distinct, the Company’s ability to provide advertisers direct access to differentiated inventory that matters to their campaigns, and the Company’s ability to reach new sources of advertiser demand and make EHR inventory more broadly available across the programmatic HCP ecosystem. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions regarding the Company’s business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with eRx platforms and EHR networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. 

OptimizeRx Contact 
Jennifer Dinkel, SVP Marketing 
jdinkel@optimizerx.com 

Investor Relations Contact 
Douglas Farrell 
LifeSci Advisors, LLC 
dfarrell@lifesciadvisors.com 

Press Inquiries 
Matter Communications 
optimizerx@matternow.com 

Partnership Inquiries
Louis Trivento, SVP Strategic Partnerships 
ltrivento@optimizerx.com 

• The four-year expansion will focus on childhood overweight and obesity prevention for over 80 million children across seven priority countries: Mexico, Colombia, Indonesia, the Philippines, India, Egypt and Kenya
• Novo will commit USD 18 million from 2026 to 2030. The four-year programme will run from 2027 to 2030, while funding begins in 2026 to support programme inception and preparation
• Childhood obesity has surpassed underweight globally for the first time on record. One in five children and adolescents aged 5 to 19 is now living with overweight, including obesity¹

Bagsværd, Denmark / New York, United States, 22 September 2026 – Novo Nordisk and UNICEF today announced a four-year expansion of their global partnership to help prevent childhood overweight and obesity, aiming to support a healthier start in life for more than 80 million children. Novo is committing USD 18 million from 2026 to 2030 to advance evidence-based policies and prevention services in seven priority countries. The expansion arrives at a turning point in global child health: childhood obesity has now surpassed underweight globally for the first time on record, according to UNICEF’s 2025 Child Nutrition Report.¹

From 2026 to 2030, the partnership will support governments to create environments that ensure healthier options are more accessible to children and families— from the food that is offered and promoted to children, to the schools, cities and health services they rely on every day.

“It is concerning that childhood obesity has surpassed underweight, affecting 1 in 10 school-aged children and adolescents globally,” said Kitty van der Heijden, Deputy Executive Director, Partnerships, UNICEF. “The moment to act is now. Through our partnership with Novo, UNICEF will work with governments to turn evidence into policies, build services, and create environments that protect children early, so every child has a fair chance to eat well, move, feel supported and grow up healthy.”

“Preventing childhood obesity requires long-term, collective action to create healthier environments for children,” said Elin Jäger, SVP, chief of staff and head of CEO Office, Corporate Strategy and Sustainability, Novo. “Through our continued partnership with UNICEF, we want to support proven prevention approaches that can become part of the systems children rely on every day, helping create healthier environments for more than 80 million children.”

Building on joint progress since 2019

Since 2019, Novo and UNICEF have helped raise childhood overweight and obesity from an under-recognised issue to a growing global policy and public health priority. Building on this foundation, the next phase of the partnership will deepen efforts in existing countries and expand to new contexts, combining evidence-based policy advocacy, technical assistance, youth-led advocacy and peer support, and social and behaviour change communication.

Scope of the expanded programme

The expanded programme will support action in Mexico, Colombia, Indonesia, the Philippines, India, Egypt and Kenya, while accelerating learning across regions.

Interventions will include:

• Growth monitoring
• Nutrition and physical activity counselling
• Peer and family support
• Community- and facility-based prevention activities
• Youth advocacy
• Basic mental health screening and support
• Legislation to promote better diets and healthy food

Success will be measured by the number of children reached by evidence-based prevention policies and interventions. Progress and challenges will be reported transparently.

The scale of the challenge

Childhood overweight and obesity now affect around 35 million children under 5 and more than 391 million children and adolescents aged 5 to 19, with 81 per cent of them living in low- and middle-income countries.¹ The impacts can be immediate and lifelong, increasing the risk of early-onset type 2 diabetes and other non-communicable diseases, while also affecting children’s wellbeing through stigma and discrimination.

Delivery will be country-led and anchored in UNICEF’s Centres of Excellence model, led from Nairobi with satellite support in Bangkok and Panama.

For further information on the partnership and programme progress, visit novonordisk.com/sustainable-business and unicef.org

UNICEF does not endorse any company, brand, organisation, product or service.

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

Contacts for further information 

Novo Nordisk Media:
Ambre James-Brown  +45 3079 9289  globalmedia@novonordisk.com	Liz Skrbkova (US)  +1 609 917 0632  USMediaRelations@novonordisk.com
Novo Nordisk Investors:
Michael Novod  +45 3075 6050  nvno@novonordisk.com	Sina Meyer   +45 3079 6656   azey@novonordisk.com
Christoffer Togo Solgaard-Tullin  +45 3079 1471  cftu@novonordisk.com
Ida Schaap Melvold  +45 3077 5649  idmg@novonordisk.com	Mads Berner Bruun  +45 3075 2936  mbbz@novonordisk.com
Frederik Taylor Pitter (US)  +1 609 613 0568  fptr@novonordisk.com	Alex Bruce (US)  +1 640 230 0276  axeu@novonordisk.com

_______________________ 
References 

1. Feeding Profit: How food environments are failing children – 2025 Child Nutrition Report – UNICEF DATA – last accessed September 2026

Attachment

• PR260922_Novo_UNICEF

Transactions during 15 September 2026 – 21 September 2026
On 7 May 2026, Alm. Brand A/S announced a share buy-back program of up to DKK 593 million, as described in company announcement no. 23/2026.

The program is carried out in accordance with the Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations.

The following transactions were made under the share buy-back program 15 September – 21 September 2026:

	Number of shares bought	Average purchase price	Amount (DKK)
Accumulated, last announcement 15 September 2026 16 September 2026 17 September 2026 18 September 2026 21 September 2026	12,127,667 59,000  255,000  204,000  250,000  259,000	16.37 17.12 17.19 17.24 17.16 17.43	198,486,915 1,010,086 4,384,215 3,517,858 4,290,900 4,513,826
Total, 15 September – 21 September 2026	1,027,000	17.25	17,716,885
Accumulated under the program	13,154,667	16.44	216,203,800

With the transactions stated above Alm. Brand A/S holds a total of 45,891,339 own shares, corresponding to 3.27% of the total number of outstanding shares.

Contact
Please direct any questions regarding this announcement to:

Investors and equity analysts:                                 

VP, Head of Investor Relations & ESG                    
Mads Thinggaard                                                       

Mobile no, +45 2025 5469                                      

Attachments

• Alm Brand_Share buyback 15 September – 21 September 2026
• AS 52 2026 – Transactions under share buyback program

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and has completed the first surgical cases with LANDMARK Total Knee System, a next-generation knee replacement solution designed to replicate healthy knee anatomy and the knee’s natural motion and support a more personalized approach to total knee arthroplasty.

As expectations for total knee arthroplasty continue to evolve, surgeons and patients are seeking the most advanced and tailored solutions when they choose a knee replacement solution. The LANDMARK Knee meets those goals through an anatomy-driven implant that was designed to leverage the full capabilities of CORI^◊ KNEE Handheld Robotics Arthroplasty.¹ The compact footprint and mobility of Handheld Robotics is optimized for use across both hospital and ambulatory surgery center (ASC) environments.

Key features of the LANDMARK Knee include:
     • Designed to replicate healthy knee anatomy and restore the natural motion and A/P position with less compromise^2-6*
     • Smooth, flat trochlear groove entry point to promote more natural patella tracking ^2,7,8*
     • Fully 3D-printed femoral component utilizing CONCELOC^◊ Technology³

“It is truly a landmark moment for Orthopaedics at Smith+Nephew. The future of knee replacement is increasingly personalized, and surgeons need technologies that help them deliver individualized care with confidence and efficiency,” said Nate Folkert, President, Smith+Nephew Orthopaedics. “Together, the natural design of LANDMARK Knee paired with CORI KNEE Handheld Robotics Arthroplasty provides a powerful solution to address the evolving needs of orthopaedic surgery.”

The first LANDMARK Knee surgical cases were completed this week by Dr. Steven MacDonald, Professor of Orthopaedic Surgery, Western University and London Health Sciences Centre in London, Ontario, who is one of the surgeons who helped with the design and development of this innovative implant system. “Knee replacement surgery has changed so much in recent years driven by the momentum of personalized medicine and an influx of innovative approaches,” explained Dr. MacDonald. “Whether achieved via the state-of-the-art new LANDMARK instrumentation system or in combination with the planning and balancing capabilities of the CORI KNEE Handheld Robotics Arthroplasty, the LANDMARK Knee provides us the flexibility to make patient-specific decisions while maintaining procedural efficiency. It is the perfect fit for surgeons looking to align with the principles of personalized care as the LANDMARK Knee was designed to meet the needs of surgeons and patients today and tomorrow.” 

Dr. Steven Haas, Chief of the Knee Service at Hospital for Special Surgery (HSS) in New York, was also a surgeon developer for the LANDMARK Knee. “The LANDMARK Knee was designed to address one of the biggest challenges in total knee arthroplasty, which is restoring anatomy without forcing unnecessary compromise,” Dr. Haas said. “Its anatomic design helps accommodate the patient’s natural anatomy while supporting personalized alignment and patellofemoral function.”

The LANDMARK Knee will be commercially introduced through a phased launch focused on early customer adoption, with broader availability across markets expected throughout 2027. Smith+Nephew will be unveiling its new knee system to HCP attendees during the American Association of Hip & Knee Surgeons (AAHKS) Annual Meeting in Dallas November 5-8. Stop by booth number 621 to see the new LANDMARK Knee in action.

To learn more, visit our LANDMARK Knee web page.

                                                                                                       – ends –  

Media Inquiries

Gina Kamler
+1 (901) 262-9070
gina.kamler@smith-nephew.com

*Compared to conventional TKA designs

References
1. Smith+Nephew 2026. Internal Report. CSD.REC.26.003_v1
2. Smith + Nephew 2026. Internal Report. CSD.REC.26.004_v1
3. Smith+Nephew 2026. Internal Report. K24-PFET/CFET
4. Grieco TF, Sharma A, Dessinger GM, Cates HE, Komistek RD. In Vivo Kinematic Comparison of a Bicruciate Stabilized Total Knee Arthroplasty and the Normal Knee Using Fluoroscopy. J Arthroplasty. 2018;33(2):565-571.
5. Almaawi A, Hutt J, Masse V, Lavigne M, Vendittoli P. Impact of mechanical and restricted kinematic alignment on Knee anatomy in Total Knee Arthroplasty. J Arthroplasty. 2017;32(7):2133-2140.
6. MacDessi SJ, Griffith-Jones W, Harris IA, Bellemans J, Chen DB. Coronal Plane Alignment of the Knee (CPAK) classification. Bone Joint J. 2021;103-B(2):329-337. 7. Smith+Nephew 2026. Verification for Femur Implants
7. Fugit W, Lenz N. “Challenging Native Patella Positions Benefit with Flat Proximal Trochlea” The International Society for Technology in Arthroplasty, 37th Annual Congress, 2026, Munich, Germany, September
8. Fugit W, Lenz N. “The Benefits of a Kinematically Designed Femoral Implant Versus Symmetric Implants” The International Society for Technology in Arthroplasty, 37th Annual Congress, 2026, Munich, Germany, September

About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $6.2 billion in 2025. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.

^◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

New director brings nephrology development expertise and over 30 years of experience in the biopharmaceutical industry

JERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Steven K. Burke, M.D., to its Board of Directors, effective September 18, 2026.

Dr. Burke brings more than 30 years of industry experience, with a particular focus on drug development for chronic kidney disease. He has worked at Akebia Therapeutics, Inc. since 2019, and has served as its Senior Vice President, Chief Research and Development Officer and Chief Medical Officer since 2021. Dr. Burke has responsibility for Akebia’s research and development functions, including research, toxicology, pharmacology, clinical operations, data management, biostatistics, clinical research, regulatory affairs, drug safety and pharmacovigilance, and medical affairs. During his time, he has had a leadership role in the development of Vafseo® (vadadustat) for anemia due to chronic kidney disease and has supported Auryxia® (ferric citrate). He also oversees development programs including praliciguat and ebribafusp alfa for glomerular diseases and other investigational programs. Prior to joining Akebia, Dr. Burke founded Abfero Pharmaceuticals, Inc. and served on its board through its acquisition by Pharmacosmos A/S. Earlier in his career, Dr. Burke served as Senior Vice President and Chief Medical Officer of Proteon Therapeutics, Inc. from 2006 to 2019 and in senior positions at several other biotechnology companies including Genzyme Inc.

“2026 has been a transformative year for SCYNEXIS following the acquisition of SCY-770, a promising drug candidate in development for Autosomal Dominant Polycystic Kidney Disease,” said Guy Macdonald, Chairman of the Board of SCYNEXIS. “As we continue to progress SCY-770, we are excited to add Steven’s deep expertise in drug development for chronic kidney disease. On behalf of the Company and my fellow Board members, I welcome Steven and we look forward to his guidance.”

“This is a very exciting time to join the SCYNEXIS Board as the Company prepares to enter Phase 2 with SCY-770,” said Dr. Burke. “SCYNEXIS has acquired a very promising asset and combined with its well-established expertise in antifungal development, is poised to become a leader in advancing therapies for severe rare diseases. I look forward to leveraging my drug development and biopharmaceutical industry experience to help SCYNEXIS deliver better outcomes for patients and create significant shareholder value.”

Dr. Burke received an A.B. from Harvard College and an M.D. from Cornell University Medical School. He completed a residency and fellowship at Brigham and Women’s Hospital and is board certified in internal medicine and gastroenterology and has maintained a Massachusetts medical license since 1989.

About SCY-770

SCY-770, a novel and highly selective, direct Adenosine Monophosphate (AMP)-activated protein kinase (AMPK) activator, is being developed as a disease-modifying therapy for ADPKD, a progressive genetic kidney disorder and the leading genetic cause of end-stage renal disease, affecting approximately 140,000 diagnosed patients in the United States. AMPK activation suppresses the mTOR and cAMP signaling pathways that drive cyst cell proliferation and fluid secretion in ADPKD, providing a mechanistically differentiated approach to slowing disease progression. SCY-770 has been evaluated in several Phase 1 trials and one Phase 2a trial in patients with nonalcoholic fatty liver disease (NAFLD). Compelling preclinical pharmacology data supports its potential utility in ADPKD. The Company aims to develop SCY-770 with the goal of reducing cyst growth and disease progression and improving patient quality of life. SCY-770 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of ADPKD.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development. For more information, visit www.scynexis.com.

Forward-Looking Statements

Statements contained in this press release regarding expected future events or results are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: the anticipated timing and results of Phase 2 trial of SCY-770, and the Company’s ability to become a leader in advancing therapies for severe rare diseases, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. For the Company, this includes the future prospects of the Company’s SCY-770 program, the timing and results of the Company’s anticipated Phase 2 proof-of-concept clinical study evaluating SCY-770, stock price volatility and uncertainties relating to the financial markets, the medical community and the global economy, and the impact of instability in general business and economic conditions, including changes in inflation and interest rates. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation, its most recent Annual Report on Form 10-K filed on March 4, 2026, including under the caption “Risk Factors,” and in other filings the Company makes with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT: 
Investor Relations
John Fraunces
LifeSci Advisors
Tel: 917-355-2395
jfraunces@lifesciadvisors.com

SALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) today announced that management will participate at the 5^th Annual ROTH Healthcare Opportunities Conference and at the Lytham Partners Investor Conference Fall Event and host 1×1 investor meetings at both conferences.

5^th Annual ROTH Healthcare Opportunities Conference
Date: September 29, 2026
Location: New York, NY
Format: 1×1 meetings
1×1 Meetings: Please contact your ROTH representative

Lytham Partners Investor Conference Fall Event
Date: September 29-30, 2026
Time of Presentation: 9:45 am ET
Location: Virtual
Format: Presentation and 1×1 meetings
1×1 Meetings: Please contact your Lytham representative
Webcast: link to webcast

A webcast of the presentation will be available on the “Events” section of the Clene website or using the webcast links above.

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Investor Contact: Kevin Gardner, LifeSci Advisors; kgardner@lifesciadvisors.com; 617-283-2856
Media Contact: Caroline Wagner, FTP; CWagner@ftpadvocacy.com; (267) 294-6563 

MONTRÉAL, Sept. 22, 2026 (GLOBE NEWSWIRE) — NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce the appointment of Mr. Guillaume Bacconnier to its Board of Directors, effective immediately.

Mr. Bacconnier holds a Master’s degree in Polymer Science. Throughout his career, he has held various commercial and operational leadership positions in seven countries. He has been a member of the Rio Tinto Group for approximately 20 years. He currently serves as General Manager of Évolys Québec Inc., a joint venture formed by Rio Tinto and Aymium, a technology company, to produce biocarbon in Canada.

In addition, the Company has approved the grant of 150,000 incentive stock options to Mr. Bacconnier. One-third of these stock options will vest immediately, with the remaining stock options subject to a two-year vesting period. The options have a term of seven years and an exercise price of $0.08 per share. The stock options were granted pursuant to the Company’s Stock Option Plan and are subject to applicable securities laws and the policies of the TSX Venture Exchange.

Message from NioBay’s President and CEO

“I am very pleased to welcome Guillaume to the Company’s Board of Directors. His drive, extensive experience in large corporations, and involvement in various strategic minerals projects will bring valuable expertise to help us advance through NioBay’s next stages of development.”

About NioBay Metals Inc.

NioBay aims to become a leader in the development of mine(s) with low carbon consumption and responsible water and wildlife management practices while prioritizing the environment, social responsibility, good governance, and the inclusion of all stakeholders. Our top priority, which is critical to our success, is the consent and full participation of the Indigenous communities in whose territories and/or on ancestral lands we operate.

In addition to other properties, NioBay holds a 100% interest in the James Bay Niobium Project located 45 km south of Moosonee, in the Moose Cree Traditional Territory of the James Bay Lowlands in Ontario. NioBay also holds an 80.2% interest in the Crevier Niobium and Tantalum project located in Québec and on the Nitassinan (ancestral territory) of the Pekuakamiulnuatsh First Nation. 

About Niobium

Niobium is a naturally occurring element. It is a metal that is ductile, malleable and highly resistant to corrosion. Because it enhances properties and functionalities, niobium is used in a wide range of materials and applications in the Mobility, Structural and Energy sectors. Niobium transforms materials. When added to materials like steel, glass and aluminum castings, niobium makes them more efficient and lowers environmental impacts, while also increased value.

About Tantalum

One of the main uses of tantalum is in the production of electronic components. Tantalum (Ta) causes no immune response in mammals, so has found wide use in the making of surgical implants. It can replace bone, for example, in skull plates; as foil or wire, it connects torn nerves; as woven gauze it binds abdominal muscle. Tantalum alloys can be extremely strong and have been used for turbine blades, rocket nozzles and internal combustion engines.

Cautionary Statements Regarding Forward-Looking Information
Certain statements in this news release constitute “forward-looking information” within the meaning of Canadian securities laws. Forward-looking statements and information may be identified by such terms as “anticipates”, “believes”, “targets”, “estimates”, “plans”, “expects”, “budget”, “scheduled”, “forecasts”, “intends”, “may”, “will”, “could” or “would” or the negative connotation thereof. These statements are necessarily based on a number of management’s beliefs, assumptions, and opinions as of the date they are made and are subject to numerous risks and uncertainties that could cause actual results and future events to differ materially from those anticipated or projected, including those risks set out in the Company’s public disclosure record on SEDAR+ (www.sedarplus.ca) under the Company’s issuer profile. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Although the assumptions made by the Company in providing forward-looking information is considered reasonable by management at the time, there can be no assurance that such assumptions will prove to be accurate and actual results and future events could differ materially from those anticipated in such information. The Company assumes no obligation to update these forward-looking statements should management’s beliefs, estimates, or opinions, or other factors, change, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release. 

FOR MORE INFORMATION, CONTACT:

NioBay Metals Inc. Jean-Sebastien David, geo. President & Chief Executive Officer Tel.: 514 866-6500 jsdavid@niobaymetals.com www.niobaymetals.com

Kimberly Darlington Investor Relations kimberly@refinedsubstance.com Tel: 514-771-3398